Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2006 1
2008 1
2009 1
2010 1
2011 2
2012 2
2013 2
2014 1
2016 6
2017 4
2018 3
2019 2
2020 1
2021 3
2022 1
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial.
Young G, Srivastava A, Kavakli K, Ross C, Sathar J, You CW, Tran H, Sun J, Wu R, Poloskey S, Qiu Z, Kichou S, Andersson S, Mei B, Rangarajan S. Young G, et al. Among authors: you cw. Lancet. 2023 Apr 29;401(10386):1427-1437. doi: 10.1016/S0140-6736(23)00284-2. Epub 2023 Mar 29. Lancet. 2023. PMID: 37003287 Clinical Trial.
Phase 3 Trial of Concizumab in Hemophilia with Inhibitors.
Matsushita T, Shapiro A, Abraham A, Angchaisuksiri P, Castaman G, Cepo K, d'Oiron R, Frei-Jones M, Goh AS, Haaning J, Hald Jacobsen S, Mahlangu J, Mathias M, Nogami K, Skovgaard Rasmussen J, Stasyshyn O, Tran H, Vilchevska K, Villarreal Martinez L, Windyga J, You CW, Zozulya N, Zulfikar B, Jiménez-Yuste V; explorer7 Investigators. Matsushita T, et al. Among authors: you cw. N Engl J Med. 2023 Aug 31;389(9):783-794. doi: 10.1056/NEJMoa2216455. N Engl J Med. 2023. PMID: 37646676 Clinical Trial.
Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial.
Srivastava A, Rangarajan S, Kavakli K, Klamroth R, Kenet G, Khoo L, You CW, Xu W, Malan N, Frenzel L, Bagot CN, Stasyshyn O, Chang CY, Poloskey S, Qiu Z, Andersson S, Mei B, Pipe SW. Srivastava A, et al. Among authors: you cw. Lancet Haematol. 2023 May;10(5):e322-e332. doi: 10.1016/S2352-3026(23)00037-6. Epub 2023 Mar 29. Lancet Haematol. 2023. PMID: 37003278 Clinical Trial.
A pediatric case of idiopathic Harlequin syndrome.
Kim JY, Lee MS, Kim SY, Kim HJ, Lee SJ, You CW, Kim JS, Kang JH. Kim JY, et al. Among authors: you cw. Korean J Pediatr. 2016 Nov;59(Suppl 1):S125-S128. doi: 10.3345/kjp.2016.59.11.S125. Epub 2016 Nov 30. Korean J Pediatr. 2016. PMID: 28018464 Free PMC article.
Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial.
Kenet G, Nolan B, Zulfikar B, Antmen B, Kampmann P, Matsushita T, You CW, Vilchevska K, Bagot CN, Sharif A, Peyvandi F, Young G, Negrier C, Chi J, Kittner B, Sussebach C, Shammas F, Mei B, Andersson S, Kavakli K. Kenet G, et al. Among authors: you cw. Blood. 2024 May 30;143(22):2256-2269. doi: 10.1182/blood.2023021864. Blood. 2024. PMID: 38452197 Free article. Clinical Trial.
33 results